Marie T. Baccara‐Dinet

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet et al. · European Heart Journal · 2015 · 534 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon et al. · Journal of clinical lipidology · 2015 · 467 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

Eli M. Roth, Marja‐Riitta Taskinen, Henry N. Ginsberg et al. · International Journal of Cardiology · 2014 · 249 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

Henry N. Ginsberg, Daniel J. Rader, Frederick J. Raal et al. · Cardiovascular Drugs and Therapy · 2016 · 214 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17